portal vein tumor thrombus
Showing 1 - 25 of >10,000
Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,
Recruiting
- Hepatocellular Carcinoma Non-resectable
- +2 more
- Cadonilimab
- +2 more
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Sep 13, 2023
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)
Recruiting
- Hepatocellular Carcinoma
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 4, 2023
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone
Completed
- Hepatocellular Carcinoma
- TACE-HAIC
- +3 more
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 8, 2022
Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)
Recruiting
- Advanced Hepatocellular Carcinoma
- Lenvatinib
- +2 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Oct 20, 2022
Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma Trial in Shanghai (radiation, combination product, drug)
Not yet recruiting
- Liver Cancer
- +4 more
- intensity-modulated radiotherapy
- +5 more
-
Shanghai, ChinaRen Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Apr 20, 2022
Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus Trial in Guangzhou (TACE combined with iodine-125 seeds
Active, not recruiting
- Hepatocellular Carcinoma
- +2 more
- TACE combined with iodine-125 seeds implantation
- TACE
-
Guangzhou, Guangdong, ChinaThe 2nd Affiliated Hospital of Guangzhou Medical University
Mar 2, 2022
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Trial in Shanghai (Tislelizumab, IMRT)
Not yet recruiting
- Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Tislelizumab
- IMRT
-
Shanghai, ChinaZhongshan hospital, Fudan University
Apr 19, 2021
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,
Not yet recruiting
- Hepatocellular Carcinoma
- +2 more
- I-125 Seeds Brachytherapy in PVTT
- +2 more
- (no location specified)
Aug 14, 2023
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) Trial in Beijing (GSMs-TACE, Surgical Resection)
Unknown status
- Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
- GSMs-TACE
- Surgical Resection
-
Beijing, ChinaBeijing Changgung Hospital
Nov 26, 2020
Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)
Unknown status
- Carcinoma, Hepatocellular
- +3 more
- Hepatic arterial infusion chemotherapy
- +2 more
-
Guangzhou, Guangdong, ChinaSecond Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020
Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))
Not yet recruiting
- Hepatocellular Carcinoma
- Sintilimab
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023
Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Guangzhou (neo-TACE-HAIC+Surgery, Surgery alone)
Recruiting
- Hepatocellular Carcinoma
- Portal Vein Thrombosis
- neo-TACE-HAIC+Surgery
- Surgery alone
-
Guangzhou, Guangdong, China
- +1 more
Oct 22, 2020
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Liver Transplantation Trial (lenvatinib, Placebo)
Not yet recruiting
- Hepatocellular Carcinoma
- +2 more
- lenvatinib
- Placebo
- (no location specified)
Mar 21, 2020
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (TACE combined with sorafenib/lenvatinib and iodion-125 seeds
Recruiting
- Hepatocellular Carcinoma Non-resectable
- TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy
- TACE combined with sorafenib/lenvatinib
-
Guangzhou, Guangdong, Chinathe Second Affiliated Hospital of Guangzhou Medical University
Jul 27, 2021
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus Trial in Shanghai (procedure, device, drug, other)
Unknown status
- Hepatocellular Carcinoma
- Portal Vein Tumor Thrombus
- Stent and Iodine-125 seed strand implantation
- +5 more
-
Shanghai, Shanghai, ChinaDepartment of Interventional Radiology, Zhongshan Hospital, Fuda
Jun 9, 2020
HCC With Portal Vein Tumor Thrombosis on Basis of Risk Scoring
Completed
- Hepatocellular Carcinoma
- +2 more
-
Daegu, DalSeo-gu, Korea, Republic ofKeimyung university Dongsan Medical Center
Aug 16, 2023
Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Hangzhou (SBRT+TACE+Sorafenib, Sorafenib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- Portal Vein Thrombosis
- SBRT+TACE+Sorafenib
- Sorafenib
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jun 15, 2020
Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus Trial (sorafenib; toripalimab)
Unknown status
- Unresectable Hepatocellular Cancer
- Portal Vein Tumor Thrombus
- sorafenib; toripalimab
- (no location specified)
Oct 23, 2019
Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in Milan (EUS-guided Portal Vein sampling)
Recruiting
- Pancreatic Cancer
- Pancreatic Adenocarcinoma
- EUS-guided Portal Vein sampling
-
Milan, ItalyIRCCS San Raffaele Scientific Institute
Jun 2, 2022
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis Trial in Canada (Neoadjuvant)
Recruiting
- Hepatocellular Carcinoma
- Portal Vein Tumour Thrombosis
- Neoadjuvant
-
Calgary, Alberta, Canada
- +6 more
Oct 18, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Toripalimab, Stereotactic body radiotherapy)
Unknown status
- Hepatocellular Carcinoma
- Toripalimab
- Stereotactic body radiotherapy
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Nov 17, 2019
HepatoCellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Sorafenib)
Completed
- HepatoCellular Carcinoma
- Portal Vein Thrombosis
- HAIC
- Sorafenib
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Oct 8, 2021
Predict Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma
Completed
- Neutrophil Extracellular Trap Formation
- Portal Vein Tumor Thrombosis
- test NETs markers
-
Qingdao, Shandong, Chinathe Affiliated Hospital of Qingdao University
Sep 2, 2021
Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombosis, Stereotactic Body Radiotherapy Trial in Hangzhou
Completed
- Hepatocellular Carcinoma Non-resectable
- +2 more
- stereotactic body raiotherapy
-
Hangzhou, Zhejiang, Chinathe second affiliated hospital of Zhejiang University
Jul 11, 2021